Hookipa pharma CEO Peters sells $20,683 in shares
- Investing.com
Market Outlook | Analysts offer mixed views, with price targets ranging from $5 to $48, reflecting uncertainty amid HOOKIPA's restructuring and pipeline shifts |
Financial Challenges | Uncover HOOKIPA's financial position: cash reserves exceeding debt, but rapid burn rate and weak gross profit margins raise concerns about long-term stability |
Pipeline Progress | Delve into HOOKIPA's ongoing collaborations with Gilead Sciences for HIV and HBV vaccines, offering potential milestone payments and royalties |
Strategic Pivot | Explore HOOKIPA's dramatic shift: 80% workforce reduction and pausing of lead program eseba-vec, signaling a new focus on the HB-700 KRAS vaccine program |
Metrics to compare | HOOK | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipHOOKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −3.6x | −0.2x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price / Book | 0.0x | 2.7x | 2.6x | |
Price / LTM Sales | 0.0x | 17.3x | 2.8x | |
Upside (Analyst Target) | - | 132.5% | 65.0% | |
Fair Value Upside | Unlock | 20.0% | 9.6% | Unlock |